Ulcerative colitis patients who went into clinical remission four months after beginning treatment with vedolizumab had a better chance of sustaining the remission, according to a study in Inflammatory Bowel Diseases. Clinical remission was evaluated by using a partial Mayo score of at least 2 with no subscore higher than 1 and a rectal bleeding subscore of zero.
Study: Sustained remission likely in UC patients taking vedolizumab
Sign up for ACG SmartBrief
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.